Switching hormone therapy using a blood test for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at whether a simple blood test (ctDNA) can tell if your current hormone therapy is starting to stop working, and whether switching to a different hormone therapy early would be better. It aims to keep your cancer under control longer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your breast cancer is ER-positive and HER2-negative and has spread to other parts of the body or is locally advanced and can't be removed with surgery
- You are taking or are scheduled to start your first line of treatment with an aromatase inhibitor (a type of hormone therapy) plus a CDK4/6 inhibitor (like palbociclib or ribociclib)
- You have not had chemotherapy for advanced breast cancer before
- You have not had brain metastases or cancer spread to the lining of the brain
- You are willing to give a tumor tissue sample and follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help doctors see how well treatment is working for advanced breast cancer that has stopped responding. It may help guide future care.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
This trial uses information from a biopsy of your tumor to help choose the best treatment for advanced or metastatic hormone receptor-positive breast cancer. The goal is to find a therapy that works better for you.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Hear when a new Metastatic Invasive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.